Lv4
780 积分 2021-07-11 加入
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis
1小时前
已完结
The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023
16天前
已完结
Diagnostic Advances and Novel Therapeutics in Peritoneal Metastasis
23天前
已关闭
Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers
23天前
已完结
Turning the tide in peritoneal metastases: Locoregional CAR-NK therapy primes systemic immunity in colorectal cancer
23天前
已关闭
Response to Ipilimumab and Nivolumab in a Patient With Malignant Peritoneal Mesothelioma
1个月前
已完结
Clinical and translational attributes of immune-related adverse events
2个月前
已完结
Association of Immune-Related Adverse Events and Efficacy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
2个月前
已完结
Immune-related adverse events and nivolumab outcomes in non-small cell lung cancer patients: A multi-institutional, retrospective cohort study
2个月前
已关闭
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
2个月前
已完结
皖公网安备34019202002308
